| Q38237522 | Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care? |
| Q90398709 | Adoptive Cell Therapy-Harnessing Antigen-Specific T Cells to Target Solid Tumours |
| Q38848219 | Adoptive Cellular Therapy (ACT) for Cancer Treatment |
| Q37316580 | Adoptive T-cell therapy for cancer: boutique therapy or treatment modality? |
| Q27004178 | Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook |
| Q36283034 | Adoptive cell therapy for the treatment of patients with metastatic melanoma |
| Q36224873 | Adoptive cell therapy with autologous tumor-infiltrating lymphocytes and high-dose interleukin-2 for metastatic melanoma: The surgeon's perspective |
| Q90326770 | Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study |
| Q37778694 | Adoptive cell therapy: genetic modification to redirect effector cell specificity. |
| Q38146713 | Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. |
| Q38178359 | Adoptive immunotherapy for cancer or viruses |
| Q38032141 | Adoptive immunotherapy of advanced melanoma |
| Q36321054 | Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape |
| Q57038247 | Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option |
| Q59072375 | Advances and Prospects in Cancer Immunotherapy |
| Q35382043 | Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement |
| Q37919589 | Biomarkers in T cell therapy clinical trials |
| Q30573747 | CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. |
| Q42136462 | CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting. |
| Q34299986 | CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma |
| Q90009975 | CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer |
| Q37279217 | CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. |
| Q37909894 | Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. |
| Q38011650 | Challenges in T cell receptor gene therapy. |
| Q50554742 | Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution. |
| Q41620209 | Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients |
| Q41915301 | Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model |
| Q36110862 | Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor |
| Q38880784 | Defining novel parameters for the optimal priming and expansion of minor histocompatibility antigen-specific T cells in culture |
| Q37412327 | Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia |
| Q47809269 | Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem Cells |
| Q35223241 | Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice |
| Q24596055 | Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy |
| Q36616920 | Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα Dependent |
| Q42381105 | Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death |
| Q35677962 | Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma |
| Q38266264 | Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes |
| Q90345252 | Enhanced Phenotype Definition for Precision Isolation of Precursor Exhausted Tumor-Infiltrating CD8 T Cells |
| Q37687429 | Enhancing adoptive immunotherapy of cancer. |
| Q37531720 | Enhancing immune responses to tumor-associated antigens |
| Q39704543 | Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy. |
| Q36107158 | Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy |
| Q37183682 | Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy |
| Q33750205 | Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs) |
| Q21328679 | Focus on adoptive T cell transfer trials in melanoma |
| Q37965815 | Genetic engineering of T cells for the immunotherapy of haematological malignancies. |
| Q39831942 | Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes |
| Q37697337 | Genetic redirection of T cells for cancer therapy. |
| Q27026627 | Genetically modified T cells in cancer therapy: opportunities and challenges |
| Q90169839 | Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients |
| Q91755802 | Highly sensitive detection of CTLA-4-positive T-cell subgroups based on nanobody and fluorescent carbon quantum dots |
| Q38371637 | How do i participate in T-cell immunotherapy? |
| Q33686985 | Hyperthermia as an immunotherapy strategy for cancer |
| Q36767295 | IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. |
| Q33839836 | IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice |
| Q42078847 | Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma |
| Q36694896 | Immune correlates of melanoma survival in adoptive cell therapy |
| Q37266668 | Immunotherapy of distant metastatic disease. |
| Q36973086 | Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells |
| Q92287926 | Inducing Tumor Suppressive Microenvironments through Genome Edited CD47-/- Syngeneic Cell Vaccination |
| Q33688931 | Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma. |
| Q59804832 | Injectable Biomimetic Hydrogels as Tools for Efficient T Cell Expansion and Delivery |
| Q92457888 | Magnetic targeting of adoptively transferred tumour-specific nanoparticle-loaded CD8+ T cells does not improve their tumour infiltration in a mouse model of cancer but promotes the retention of these cells in tumour-draining lymph nodes |
| Q43129884 | Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy. |
| Q28085769 | Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies |
| Q27309991 | Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells |
| Q38849182 | Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells. |
| Q36127769 | Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma |
| Q37963294 | Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses |
| Q48112031 | N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner. |
| Q97644519 | Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal |
| Q55352057 | Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment. |
| Q36475411 | Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale |
| Q37783804 | Pluripotent stem cell-derived natural killer cells for cancer therapy |
| Q38665128 | Predictors of tumor-infiltrating lymphocyte efficacy in melanoma |
| Q61698755 | Principles of adoptive T cell therapy in cancer |
| Q42549343 | Promoting thiol expression increases the durability of antitumor T-cell functions |
| Q27311367 | Quantifying biomass changes of single CD8+ T cells during antigen specific cytotoxicity |
| Q37065838 | Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. |
| Q34307987 | Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells |
| Q35860034 | Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment |
| Q37236693 | Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy |
| Q30535187 | Sleeping beauty system to redirect T-cell specificity for human applications |
| Q27002575 | Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? |
| Q42695310 | Syngeneic syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting |
| Q37713498 | Systematic evaluation of immune regulation and modulation |
| Q52596337 | T Cell Dysfunction in Cancer. |
| Q38068003 | T cell-based gene therapy of cancer |
| Q38170497 | TCR repertoires of intratumoral T-cell subsets |
| Q36057454 | TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. |
| Q37152606 | Telomere length dynamics in human memory T cells specific for viruses causing acute or latent infections |
| Q37677403 | Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion |
| Q47252754 | The Role of Tumor Microenvironment in Cancer Immunotherapy. |
| Q37687418 | The evolving role of dendritic cells in cancer therapy |
| Q37768258 | Thoracic metastasectomy for adoptive immunotherapy of melanoma: a single-institution experience |
| Q39655893 | Tumor Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Analysis of Tumors Resected for TIL |
| Q37320131 | Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma. |
| Q29616128 | Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 |
| Q38636573 | Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. |
| Q84107453 | Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes |
| Q39541801 | Value of large scale expansion of tumor infiltrating lymphocytes in a compartmentalised gas-permeable bag: interests for adoptive immunotherapy |